News

Financed through a combination of bank debt and bonds, the acquisition amounts to about $158 for each of Salix’s outstanding shares, and will be followed by a merger

For the NDA, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of 11 August 2015. Cobimetinib is a specific MEK inhibitor discovered by

Malaysia is the 20th country to approve the company’s Phase III trial, which has now enrolled more than 350 patients with advanced primary, not yet treated, head and

Currently, Questcor operates as the autoimmune and rare diseases business of Mallinckrodt Pharmaceuticals. In Canada, Synacthen Depot is approved for therapeutic use in patients diagnosed with many difficult-to-treat

Recently, the company has also leased a clinical manufacturing facility in Santa Monica, California. The expansion of the manufacturing capabilities will help the firm to support the development

The deal will see the two companies supply panels of antibodies to develop bispecific antibody products using Genmab’s DuoBody platform technology. If a product candidate is developed for

The research alliance will focus on GI sensory and motor mechanisms underlying functional bowel disorders and GI motility disorders. The University’s Neurogastroenterology Group aims to understand the neuromuscular

As part of the deal, J-Network has an exclusive one-year renewable license for the marketing and sales of TRGM’s proprietary product, designed to improve sleep and immune function,

The company focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nanoparticulates, drug/device combination products, solid solutions